Source comparison
Shoulder Injury Peptides 2026 Update: Comparison
BPC-157 VEGF upregulation, angiogenesis Rotator cuff tears, tendon avulsions 500mcg daily SC for 8–12 weeks University of Split RCT (2025): 62% reduction in adhesions, 4.3-week earlier ROM recovery Strongest evidence for post-surgical tendon repair. Measurable
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis
- Rotator cuff tears, tendon avulsions
- 500mcg daily SC for 8–12 weeks
- University of Split RCT (2025): 62% reduction in adhesions, 4.3-week earlier ROM recovery
- Strongest evidence for post-surgical tendon repair. Measurable outcomes across multiple trials
- TB-500 (Thymosin Beta-4)
- Actin polymerization, fibroblast migration
- Tendon adhesions, impaired glide mechanics
- 5–10mg weekly IM for 6–8 weeks
- Equine Veterinary Journal (2023): 6.8-week earlier return to training, 35% better fiber alignment
- Mechanism is conserved across species. Human trials underway, veterinary data robust
- GHK-Cu
- Collagen I/III remodeling, TGF-beta inhibition
- Post-surgical fibrosis, scar tissue restriction
- 1–2mg daily SC or topical application
- Johns Hopkins pilot (2024): 47% higher Type I collagen density, 29% greater passive ROM
- Anti-fibrotic effect is the differentiator. Prevents restrictive adhesions without impairing healing